Puig, L., Bakulev, A. L., Kokhan, M. M., Samtsov, A. V., Khairutdinov, V. R., Morozova, M. A., . . . Zinkina-Orikhan, A. V. (2021). Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial. State Scientific Center of Dermatovenereology and Cosmetology.
Chicago Style (17th ed.) CitationPuig, Luis, et al. Efficacy and Safety of Netakimab, a Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of a 54-week Randomized Double-blind Placebo-controlled PLANETA Clinical Trial. State Scientific Center of Dermatovenereology and Cosmetology, 2021.
MLA (8th ed.) CitationPuig, Luis, et al. Efficacy and Safety of Netakimab, a Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of a 54-week Randomized Double-blind Placebo-controlled PLANETA Clinical Trial. State Scientific Center of Dermatovenereology and Cosmetology, 2021.